SIGA Technologies Inc. has presented a management presentation focusing on its leadership in global health and infectious diseases. The company highlighted its achievements in advancing strategic initiatives, enhancing national health security, and driving shareholder value through the delivery of TPOXX to U.S. and global government agencies. With over $1 billion in procurement contracts from a decade of collaboration with governments, SIGA has sold products in over 30 countries. TPOXX, a foundational franchise and trusted treatment for smallpox, is approved in the U.S., Canada, Europe, UK, and Japan. The company reported strong financial performance, with significant TPOXX revenue and robust gross margins from 2020 to 2024. SIGA continues to focus on regulatory submissions for new TPOXX indications and exploring opportunities for geographic and inorganic growth. You can access the full presentation through the link below.